Ribociclib
Kisqali (ribociclib) is a small molecule pharmaceutical. Ribociclib was first approved as Kisqali on 2017-03-13. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against cyclin-dependent kinase 4. Kisqali's patents are valid until 2036-04-14 (FDA).
| Trade Name | Kisqali |
|---|---|
| Common Name | Ribociclib |
| Indication | breast neoplasms |
| Drug Class | Cyclin dependent kinase inhibitors |
